- Home
- LDI vs TSHA Comparison
LDI vs TSHA Comparison
Compare LDI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDI | TSHA |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 954.8M | 1.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LDI | TSHA |
|---|---|---|
| Price | $2.14 | $5.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $3.00 | ★ $10.22 |
| AVG Volume (30 Days) | ★ 3.8M | 3.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,095,780,000.00 | $6,310,000.00 |
| Revenue This Year | $24.99 | N/A |
| Revenue Next Year | $18.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.74 | N/A |
| 52 Week Low | $1.01 | $1.05 |
| 52 Week High | $5.05 | $6.02 |
Technical Indicators
Market Signals| Indicator | LDI | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 34.53 | 61.09 |
| Support Level | $2.11 | $5.37 |
| Resistance Level | $2.88 | $6.02 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 1.94 | 77.72 |
Price Performance
Historical ComparisonAbout LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.